ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update
May 11, 2021 16:15 ET | ARCA biopharma, Inc.
Topline data from Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the third quarter of 2021 WESTMINSTER, Colo., May 11, 2021 (GLOBE NEWSWIRE) -- ARCA...
Christopher Graybill Joins ARCA as Vice President, Clinical Development
May 05, 2021 16:05 ET | ARCA biopharma, Inc.
WESTMINSTER, Colo., May 05, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
ARCA biopharma Announces C. Jeff Dekker to be Appointed Chief Financial Officer
May 03, 2021 16:30 ET | ARCA biopharma, Inc.
WESTMINSTER, Colo., May 03, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update
March 18, 2021 16:30 ET | ARCA biopharma, Inc.
Topline data from Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the third quarter of 2021 New patent issued by USPTO for use of Gencaro in treating...
ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19
December 15, 2020 08:30 ET | ARCA biopharma, Inc.
rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients, including after availability of vaccinesrNAPc2 is the only novel compound being developed for COVID-19...
ARCA Logo - JPEG.jpg
ARCA biopharma Announces Location Change for 2020 Annual Meeting of Stockholders
December 09, 2020 17:40 ET | ARCA biopharma, Inc.
WESTMINSTER, Colo., Dec. 09, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that its 2020 Annual Meeting of Stockholders, scheduled for Thursday, December 10, 2020 at...
AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation
November 23, 2020 08:30 ET | ARCA biopharma, Inc.
Development addresses need for treatments for patients hospitalized with COVID-19 whether vaccines are available or notAB201 is the only novel compound being developed for COVID Associated...
ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update
November 02, 2020 08:30 ET | ARCA biopharma, Inc.
Initiation of Phase 2b clinical trial evaluating AB201 as a potential treatment for COVID19 anticipated in fourth quarterTopline data from trial anticipated Q2 2021 WESTMINSTER, Colo., Nov. 02,...
ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19
October 07, 2020 08:30 ET | ARCA biopharma, Inc.
Initiation of Phase 2b clinical trial anticipated in Q4 2020Trial to enroll approximately 100 patients hospitalized with COVID-19Topline data anticipated Q2 2021 WESTMINSTER, Colo., Oct. 07, 2020 ...
ARCA Logo - JPEG.jpg
ARCA biopharma Announces Promotion of Chief Medical Officer and Vice President, Regulatory Affairs & Quality
October 05, 2020 16:30 ET | ARCA biopharma, Inc.
WESTMINSTER, Colo., Oct. 05, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...